Geode Capital Management LLC Raises Stake in Edwards Lifesciences Co. (NYSE:EW)

Geode Capital Management LLC raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 0.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,647,341 shares of the medical research company's stock after purchasing an additional 126,194 shares during the period. Geode Capital Management LLC owned 2.31% of Edwards Lifesciences worth $1,007,520,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Townsquare Capital LLC lifted its position in shares of Edwards Lifesciences by 20.5% during the third quarter. Townsquare Capital LLC now owns 5,208 shares of the medical research company's stock worth $344,000 after purchasing an additional 886 shares during the last quarter. Public Sector Pension Investment Board boosted its position in Edwards Lifesciences by 12.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 26,167 shares of the medical research company's stock valued at $1,727,000 after buying an additional 2,900 shares during the period. Edgestream Partners L.P. grew its stake in Edwards Lifesciences by 117.1% in the third quarter. Edgestream Partners L.P. now owns 10,294 shares of the medical research company's stock worth $679,000 after purchasing an additional 5,552 shares in the last quarter. Erste Asset Management GmbH purchased a new position in Edwards Lifesciences during the 3rd quarter worth $1,298,000. Finally, Point72 Hong Kong Ltd bought a new position in Edwards Lifesciences in the third quarter worth about $66,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,553 shares of company stock worth $4,513,064. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

EW traded down $0.66 during trading on Monday, hitting $68.70. The company's stock had a trading volume of 2,292,137 shares, compared to its average volume of 4,837,067. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business's fifty day simple moving average is $71.74 and its 200 day simple moving average is $70.66. The firm has a market capitalization of $40.39 billion, a price-to-earnings ratio of 9.81, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

EW has been the subject of several recent analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and upped their target price for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price target for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Citigroup increased their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Finally, Morgan Stanley upped their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.